FreeTheAI

Veradermics Sets Call to Review Phase 3 Data for Hair Loss Drug VDPHL01

MixedHigh impact
MANE$108.82 −5.43%

Veradermics, Incorporated (MANE) scheduled a conference call and webcast for Oct. 19, 2026, at 8:00 a.m. ET to present topline results from Part A of its Phase 3 304 clinical trial. The study evaluates VDPHL01, an extended-release oral minoxidil candidate, in more than 500 male patients diagnosed with mild-to-moderate pattern hair loss. Ahead of the announcement, shares of the company were down 5.43% at $108.80.

The Phase 3 304 study represents a pivotal trial evaluating co-primary endpoints at Month 6. If cleared by regulatory authorities, VDPHL01 could become the only FDA-approved oral non-hormonal treatment option for pattern hair loss. The overall clinical program covers three Phase 3 trials that will eventually assess over 1,600 participants across its entire dataset.

Investors will monitor the upcoming webcast for initial efficacy and safety outcomes, including measures such as TAHC and AAIRS. Future regulatory updates and results from the remaining Phase 3 trials will serve as key factors for the commercial development path of VDPHL01.

Key points

  • Veradermics, Incorporated (MANE) will host a webcast on Oct. 19, 2026, at 8:00 a.m. ET to review Phase 3 data.
  • The Part A trial tested extended-release minoxidil candidate VDPHL01 in over 500 men with pattern hair loss.
  • Study results focus on Month 6 co-primary endpoints to help establish regulatory clearance prospects.
  • If approved, VDPHL01 could be the first FDA-approved oral non-hormonal hair loss treatment option.
  • Shares of Veradermics traded at $108.80, down 5.43% on the day ahead of the announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

When will Veradermics host its Phase 3 trial data call?

Veradermics, Incorporated will host a webcast on Oct. 19, 2026, at 8:00 a.m. ET to present Phase 3 topline results.

What condition is VDPHL01 designed to treat?

VDPHL01 is an extended-release oral minoxidil formulation being developed to treat mild-to-moderate pattern hair loss.

How many patients are in the Veradermics Phase 3 program?

The complete Phase 3 program spans three trials involving more than 1,600 total study participants.